Saturday 17 October 2026
Export RDGT’s income statement to Excel — free account
Ridgetech Inc.
RDGT Healthcare Pharmaceutical Retailers
Ridgetech Inc.’s revenue for fiscal 2026 (year ended March 2026) was $132.2 million, up 10.2% from fiscal 2025. Insiders bought in the last twelve months.
0.84
0.01
+1.20%
Follow RDGT
| Sep '25 | Mar '23 | Sep '22 | Mar '22 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 4 | 6 | 3 |
+8 more TTM periods Free account |
| 0.00% | (114.72%) | (15.90%) | (37.28%) | ||
| 0.00% | (24.67%) | (3.84%) | (9.05%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | (137.93%) | (18.62%) | (44.83%) | |
Average Days of Receivables |
0.00 | 19.63 | 32.03 | 34.86 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
10.76 | (8.67) | 8.06 | (5.10) | |
| Other line items | |||||
Cash ROIC |
22.50% | (17.48%) | 15.26% | (8.57%) | |
Accounts Receivable Turnover |
0.00 | 17.74 | 13.46 | 12.49 | |
Accounts Payable Turnover |
0.00 | 8.52 | 9.01 | 7.08 | |
Inventory Turnover |
0.00 | 14.95 | 13.11 | 12.40 | |
Average Days of Payables |
0.00 | 40.64 | 50.09 | 53.96 | |
Days of Inventory on Hand |
0.00 | 23.27 | 30.10 | 32.76 | |
Tax Rate |
— | 0.07 | 0.63 | 0.13 | |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | 30.10% | 23.35% | 25.46% | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.36 | (2.05) | 0.53 | |
Depreciation/Fixed assets |
160.79 | 0.10 | 0.10 | 0.09 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates